Organogenesis Holdings (ORGO) has capped FY 2025 with fourth quarter revenue of US$225.6 million and basic EPS of US$0.28, with trailing twelve month revenue at US$564.2 million and basic EPS of US$0.16. Over recent periods the company has seen quarterly revenue move from US$126.7 million in Q4 2024 to US$225.6 million in Q4 2025, while quarterly EPS shifted from US$0.05 to US$0.28 over the same span, as trailing twelve month EPS moved from roughly breakeven at US$0.01 to US$0.16. For investors, the latest results point to a story centered on how much of this earnings profile is being driven by margins rather than pure top line momentum.

See our full analysis for Organogenesis Holdings.

With the headline numbers on the table, the next step is to weigh them against the prevailing narratives around Organogenesis, seeing where the recent margin and profitability trends line up with expectations and where they push the story in a different direction.

Profit swings and margins take center stage

• Across FY 2025, quarterly net income moved from a loss of US$21.6 million in Q1 to a profit of US$35.1 million in Q4, with trailing twelve month net income at US$20.0 million by year end.
• Bulls point to this shift to profitability and highlight forecasts that earnings could grow about 40.6% per year. However, the same dataset shows the five year average earnings trend at a large negative rate, so:
  • Trailing twelve month EPS only recently turned positive at US$0.16 after periods where it sat below zero. This keeps the bullish earnings ramp in early days relative to that longer weak stretch.
  • The move from a trailing twelve month loss of US$20.4 million at Q1 2025 to a profit of US$20.0 million at Q4 2025 heavily supports the bullish focus on margin improvement. It also underlines how quickly the earnings picture has flipped compared with that five year history.

Over this kind of swing, bulls argue the business is finally moving onto a more durable profit footing, but the relatively short profitable window means there is still a lot to prove about how long that can last. 🐂 Organogenesis Holdings Bull Case

Revenue softness versus earnings growth story

• On a trailing twelve month basis, revenue is recorded at US$564.2 million for Q4 2025, while separate analysis expects revenue to decline by about 1.2% per year over the next three years.
• Bears focus on this projected revenue slippage and recent commentary around a 23% year over year product revenue decline, arguing that margin gains alone may not offset softer top line, and the numbers create a few pressure points:
  • The trailing twelve month revenue path in the dataset, from US$482.0 million at Q4 2024 to US$564.2 million at Q4 2025, sits in contrast to expectations of a 1.2% annual decline ahead. This is what fuels the concern that recent strength might not be repeated.
  • References to segment declines and lower gross profit margins to 73% from 78% are consistent with the idea that pricing and mix are already a headwind. The bearish case therefore leans heavily on the risk that similar pressures could weigh on how much earnings growth actually comes through even after the latest profitable year.

Skeptics warn that if the revenue path starts to look more like those decline forecasts while margins stay under pressure, the recent EPS recovery could prove harder to maintain than the latest quarter suggests. 🐻 Organogenesis Holdings Bear Case

P/E sits below peers at 20.6x

• The trailing P/E multiple is reported at 20.6x, compared with 23x for the wider US biotechs industry and 38.3x for the closer peer group, while the current share price is US$3.21 against an analyst consensus price target of US$8.00.
• Consensus narrative flags this relative valuation gap alongside expected earnings growth and margin expansion, and the figures give investors a few concrete reference points:
  • The combination of a 20.6x P/E and recently positive trailing twelve month EPS of US$0.16 means the market is already paying for that new profitability, but at a lower multiple than both the broader industry and the peer set in the data.
  • Analysts linking their US$8.00 price target to earnings of US$114.0 million by around 2028 and higher projected margins are effectively saying that the current price of US$3.21 does not yet reflect those profit expectations, even as the trailing numbers only just crossed into positive territory over the last year.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Organogenesis Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed signals around profit, margins, and revenue can feel hard to read, so it is worth checking the full picture for yourself and weighing both sides, especially since our work highlights that there are 4 key rewards and 1 important warning sign to keep in mind as you form your own view.

See What Else Is Out There

Organogenesis is working through a mix of softer revenue expectations, margin pressure, and only recently positive earnings, which leaves significant uncertainty.

If that mix of fragile profitability and revenue questions makes you uneasy, compare it with our 76 resilient stocks with low risk scores that spotlights companies with steadier profiles you can review right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.